RxDoctor Payments Data

Andrea Mignatti, MD

Interventional Cardiology · Manhasset, NYNPI 1245464577

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (49.9%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Medtronic at 36.7% of the total. 2025 is the largest year on record at $12,925, 7.3 times the $1,770 reported in 2019.

$35,322in general payments, 2019–2025

Across 368 payments — averaging $95.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$13K
  • Inari Medical, Inc.$5K
  • Edwards Lifesciences$4K
  • Abiomed$3K
  • Boston Scientific$3K
  • W. L. Gore & Associates, Inc.$2K
  • plus $6K from 16 others
$77,367in research payments, 2019–2025

Across 17 payments — averaging $4550.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$77K

What the payments were for

  • Consulting fees$1,2003%
  • Travel & lodging$16,29146%
  • Food & beverage$17,63750%
  • Education$1931%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,322 in reported general payments places this provider in the 75th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York →

Medicare billing

Part B allowed, 2024
$55,962
Medicare patients
97
Services billed
240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban12$7,833
Metoprolol Succinate37$497
Atorvastatin Calcium49$221
Losartan Potassium18$193
Amlodipine Besylate13$52
Hydrochlorothiazide17$42

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Manhasset

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →